Since the French government launched its vaccination campaign against the coronavirus (COVID-19) on December 27, 2020, the number of vaccinated people in France steadily rose. As of January 1, 2023, 79 percent of the French population has received three vaccine doses against the coronavirus. With 83 percent of vaccinated people, the French region with the highest vaccination rate was Brittany. On the other hand, only 67 percent of people in Corsica were fully vaccinated (three doses) against the coronavirus.

Since France launched its vaccination campaign to fight the COVID-19 pandemic on December 27, 2020, around 70 percent of the French population received three doses of vaccine against the coronavirus. As of June 26, 2023, the share of unvaccinated people in France reached 14 percent. From an age group perspective, people aged 70 to 74 were the most fully vaccinated age group in France. On the other hand, 96.5 percent of children aged five to nine were not vaccinated against COVID-19.

In France, 53.8 million people have received the two doses required for complete vaccination against COVID-19 as of July 2023. France launched its vaccination campaign against the coronavirus epidemic (COVID-19) on December 27, 2020. Since then, the number of people who received at least one dose of vaccine amounted to some 54.7 million, according to the French national health agency figures. In addition, 41 million people received a booster shot (a third vaccine dose) in France. The recent evolution of COVID-19 in France As of December 2023, France's cumulative number of COVID-19 infections reached 39 million. France registered over 20,000 cases of COVID-19 within a week (between April 26 and May 3). As of December 2023, France's COVID-19 death toll stood at 168,000 deaths. The hospital situation in France As of May 2022, the country registered around 12,700 hospital patients due to COVID-19. At the same time, just over 700 ICU patients were in French intensive care units due to the coronavirus. According to the geographical distribution of patients, Parisian ICUs treated the highest number of patients.

Actual value and historical data chart for France Immunization Measles Percent Of Children Ages 12 23 Months

France FR: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 90.000 % in 2017. This stayed constant from the previous number of 90.000 % for 2016. France FR: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 84.000 % from Dec 1983 (Median) to 2017, with 35 observations. The data reached an all-time high of 91.000 % in 2015 and a record low of 15.000 % in 1983. France FR: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank.WDI: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

In France, the number of mandatory vaccines increased from ***** to ****** for children born from January 2018. These vaccines are for Diphtheria, Tetanus, Poliomyelitis, Pertussis, Hemophilus B, Hepatitis B, Meningitis, Pneumococcus, Mumps, Measles, and Rubella. As of 2018, over ** percent of children aged 24 months received a DTP vaccination (Diphteria, Tetanus, and Pertussis), whereas the meningococcal C immunization stood at **** percent. Nonetheless, certain immunizations can differ on an individual basis due to medical circumstances.

Actual value and historical data chart for France Immunization Dpt Percent Of Children Ages 12 23 Months

In 2020, the majority of the French population, aged 18 to 75 years old, were generally favorable to vaccines. During that year, over ** percent of the French population was very favorable to vaccines. On the other hand, over ** percent of French people were not in favor of vaccines. Over the last two decades, skepticism towards vaccines fluctuated in the country, reaching as low as *** percent in 2000 to ** percent in 2010. The public opinion towards vaccines was especially low in 2010, which could be linked to France's management of the H1N1 influenza virus (swine flu pandemic).

Context

"Experts have warned that the race to produce a Covid-19 vaccine could make the pandemic worse in the long run. A weak or partially effective candidate could potentially result in people believing they are immune to the virus, resulting in higher rates of infection. That warning was recently voiced by Professor Richard Peto of Oxford University and an adviser to the World Health Organization, who said that the first vaccine would be distributed all over the world, even if it had low efficacy."

" Around the world, some publics are extremely cautious about a vaccine and remain reluctant to take one, with the vast majority of respondents citing potential side effects as a reason to avoid getting one."

"So where are people least concerned about taking a Covid-19 vaccine if it was available? Ipsos MORI found that 97 percent of people in China would take one, along with 88 percent in Brazil, 87 percent in India and 85 percent in the UK. Russia recently announcing that it was aiming to bring its Sputnik V vaccine to the market at some stage this month, despite the fact that it did not undergo large scale testing. Only 54 percent of Russians say they would take a vaccine if it was available, with the share of people in France also low at 59 percent. In both Germany and the United States, 67 percent of respondents say they would agree to take a vaccine, according to the research." https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Content

This chart shows the share who agree/disagree they would take a Covid-19 vaccine if it was available. Source: Ipsos MORI

Acknowledgements

Source: Ipsos MORI Niall McCarthy, Data Journalist. https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Photo by Markus Winkler on Unsplash

Inspiration

Covid-19.

1For this age group, the figure was obtained from Ref. [36].

Actual value and historical data chart for France Immunization Hib3 Percent Of Children Ages 12 23 Months

In 2020, reluctance towards certain vaccines were common among the French population. Over *** percent of the population was unfavorable towards the vaccine against seasonal influenza, followed by Hepatitis B and other unspecified hepatitis. In addition, **** percent of French respondents stated to be unfavorable to new vaccines such as the ******** vaccine.

Invasive meningococcal disease is a life-threatening infection preventable through vaccination. Pediatric vaccination rates have declined during the coronavirus disease 2019 (COVID-19) pandemic. This survey aimed to understand how parents’ attitudes and behaviors have changed during the pandemic with regard to immunization and, more specifically, meningococcal vaccination. An online survey was emailed to parents of eligible children 0–4 years, following the selection process from UK, France, Germany, Italy, Brazil, Argentina, and Australia; and of adolescents 11–18 years from US. Data collection took place 19 January–16 February 2021. Quotas were set to ensure a representative sample. Eleven questions relating to general perceptions around vaccination and attitudes and behaviors toward meningitis vaccination were displayed. On 4,962 parents (average 35 years) participating in the survey, most (83%) believed important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Nearly half of routine vaccine appointments were delayed or canceled due to the pandemic, and 61% of respondents were likely to have their children catch up once COVID-19 restrictions were lifted. 30% of meningitidis vaccination appointments were canceled or delayed during the pandemic, and 21% of parents did not intend to reschedule them because of lockdown/stay at home regulations, and fear of catching COVID-19 in public places. It is crucial to communicate clear instructions to health workers and the general population and to provide appropriate safety precautions in vaccination centers. This will help to maintain vaccination rates and limit infections to prevent future outbreaks. What is the context?Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death.Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis.Vaccination rates have declined during the coronavirus (COVID-19) pandemic. Invasive meningococcal disease (IMD) is an uncommon infection that can lead to permanent disabilities and even death. Meningitis vaccination can prevent IMDs caused by Neisseria meningitidis. Vaccination rates have declined during the coronavirus (COVID-19) pandemic. What is new?We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic.Results were reviewed by health care professional experts as well as by patient authors (IMD survivors).Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic.Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19.Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. We collected opinion of parents from the UK, France, Germany, Italy, Brazil, Argentina, Australia, and the US, to understand their attitudes and behaviors toward meningitis vaccination during the COVID-19 pandemic. Results were reviewed by health care professional experts as well as by patient authors (IMD survivors). Most (83%) of the 4,962 parents believed that it is important for their child to continue receiving recommended vaccines during the COVID-19 pandemic. Half of the scheduled appointments for meningitis vaccination were canceled or delayed during the COVID-19 pandemic, mainly due to lockdown regulations and fear of catching COVID-19. Twenty-one percent of the parents who had their child’s meningitis vaccination appointment canceled, did not intend to reschedule it. What is the impact?It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken.Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic. It is crucial that clear information is communicated by health care authorities and practitioners about the availability of vaccination during pandemic and the safety precautions that are taken. Collected opinions emphasize the importance of continuing vaccinations against infectious diseases during a pandemic.

During the season 2020-2021, the influenza vaccine coverage among the French population aged under ** reached nearly ** percent, and among those aged 65 and over roughly ** percent. The influenza vaccine is particularly recommended for certain categories of people who are likely to have a severe form of influenza and more fragile people such as people aged 65 and older. Compared to the previous season (2019-2020), the share of people who received a flu shot increased by *** percent among those aged 65 and older.

Influenza is a contagious respiratory infection that can be caused by several types of influenza virus (A, B, or C). These viruses evolve, and each fall, the composition of the vaccine is adapted to the circulating viruses. Vaccination involves a single injection but must be renewed each year due to these changes in composition.

attention: these data will no longer be updated after 23 June 2023 As part of its mission to support the management of the health crisis, the Directorate of Research, Studies, Evaluation and Statistics (DREES) uses pseudonymised data from the three main databases on the Covid-19 crisis: Si-VIC (hospitalisation), SI-DEP (screening) and VAC-SI (vaccination).

These farms lead to numerous analyses, published or for use by crisis management actors, on the three themes: screening, hospitalisation and vaccination.DREES also makes crossovers between these bases, in order to shed light on issues that fall under several of these themes in a joint way. Thus, a regular follow-up according to the vaccination status of the number of positive cases in the Covid-19 tests and hospital admissions is carried out. Similarly, comparative analyses of the frequencies of severe Covid-19 cases depending on the variant or identified mutations of the virus affecting patients may be conducted. These data cover all ages and France as a whole. The percentages of the Omicron variant among the positive tests are estimated via a proxy on the screened tests. These percentages are not significant before the onset of the Omicron variant.

NB: changes in the management of the Covid epidemic earlier this year have had an impact on data quality. Since February 1, 2023, in order to receive a test result certificate, the patient must have previously consented to the sharing of his personal data for this purpose. The constitution of the pseudonym (non-signifying character string uniquely identifying each person) took place from 1 February upstream of SI-DEP for people who do not give their consent for the sharing of their personal data, so that they are not integrated into the information system, while ensuring epidemiological surveillance. DREES found anomalies on the pseudonyms received for the tests validated since 1 February. These anomalies degraded the quality of SI-DEP matching with other SI-VIC and VAC-SI data sources. Investigations have made it possible to identify several causes for anomalies concerning the pseudonym in this stream and corrective actions have been implemented prior to the sending of pseudonymised data to the DREES.

These corrections were fully operational from the data collected on 17 February, without the possibility of correcting the previous days. For this reason, the test data for the period from 1 to 16 February are not disseminated in the datasets published by the DREES (the columns related to SI-DEP, for the period from 1 to 16 February are therefore not included).

Immunization, Pol3 (% of one-year-old children) in France was reported at 96 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. France - Immunization, Pol3 (% of one-year-old children) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

As of November 2021, the French population was rather trustful of the government's ability to successfully perform its vaccination campaign against COVID-19. According to this survey, ** percent of respondents trusted in the government's performance in its vaccine campaign. On the other hand, *** out of five respondents had very little trust.

While the vaccination campaign is accelerating in France, where more than *********** people have already received the first dose of the vaccine, the prospect of a "vaccination passport" seems to be making its way among the French. Regarding store attendance, more than ***** out of five French people having political affinity with the Republicans party were in favor of mandatory vaccination for people wishing to go to the stores in ************. This proportion did not exceed ** percent among people close to the Parti Socialiste and La France Insoumise.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Since the start of the vaccination campaign against the new coronavirus (Covid-19) in France, a share of the population has suffered from adverse effects. However, a majority of these reactions were not serious. As of June 10, 2021, French health authorities indeed recorded 26 percent of severe adverse reaction cases caused by the injection of one of the vaccines developed against the Covid-19 virus.